Which second-line biologic after anti-TNF failure during Crohn's disease: Ustekinumab or vedolizumab, a multicentre retrospective study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Crohn's and Colitis Année : 2020

Which second-line biologic after anti-TNF failure during Crohn's disease: Ustekinumab or vedolizumab, a multicentre retrospective study

, (1) , (2) , (3) , (4) , (5) , (6, 7) , , (4) , (8) , (5) , (9) , (5)
1
2
3
4
5
6
7
8
9
Fichier non déposé

Dates et versions

hal-03551537 , version 1 (01-02-2022)

Identifiants

  • HAL Id : hal-03551537 , version 1

Citer

C. Rayer, X. Roblin, D. Laharie, B. Caron, M. Flamant, et al.. Which second-line biologic after anti-TNF failure during Crohn's disease: Ustekinumab or vedolizumab, a multicentre retrospective study. Journal of Crohn's and Colitis, 2020, 14 (1), pp.S547. ⟨hal-03551537⟩
14 Consultations
0 Téléchargements

Partager

Gmail Facebook Twitter LinkedIn More